Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept
摩根士丹利表示,Bitopertin試驗未達到次要終點增加了監管路徑的不確定性,將Disc藥物的目標股價從75美元下調至40美元;保持同等權重
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊